Disclosure Notice – Thomas Brankin

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Promisia Healthcare Limited
Date this disclosure made:
9/08/2023
Date of last disclosure:
31/03/2021 (SPH notice)
Director or senior manager giving disclosure
Full name(s):
Thomas Brankin
Name of listed issuer:
Promisia Healthcare Limited
Name of related body corporate (if applicable):
N/A
Position held in listed issuer:
Executive Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products:
Ordinary Shares
Nature of the affected relevant interest(s):
Beneficial interest
For that relevant interest-
Number held in class before acquisition or disposal:
11,237,165,711
Number held in class after acquisition or disposal:
11,267,898,011
Current registered holder(s):
Garrick Robert Wells, Pamela Orene
Wells, Catherine Anne Wells, Sarah
Jane Gibbs, Independent Trust
Company (2006) Limited, Phillip
David Wells
Registered holder(s) once transfers are registered:
Thomas David Brankin and Michael
John Kirwin Lay as trustees of the
Brankin Family Interest Trust
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative:
N/A
Class of underlying financial products:
N/A
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 6

Details of transactions requiring disclosure-
Date of transaction:3/08/2023
Nature of transaction:
Off market share transfer
Name of any other party or parties to the transaction (if known):
Garrick Robert Wells, Pamela Orene
Wells, Catherine Anne Wells, Sarah
Jane Gibbs, Independent Trust
Company (2006) Limited, Phillip
David Wells
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
(1) $0.009 per share (2) $0.001 per
share
Number of financial products to which the transaction related:
(1) 15,915,613 shares (2)
14,816,687 shares
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the following details—
Whether relevant interests were acquired or disposed of during a closed period:No
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
N/A
Date of the prior written clearance (if any):
N/A
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:N/A
Nature of relevant interest:N/A
For that relevant interest,-
Number held in class:N/A
Current registered holder(s):N/A
For a derivative relevant interest,-
Type of derivative:N/A
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:Matt Yates, Solicitor
09/08/2023

Notes
Use this form to disclose all the acquisitions and disposals by a director or senior
manager of a listed issuer, or of a related body corporate, or in specified derivatives.
The disclosure must be made within—
(a) 20 working days after the first acquisition or disposal disclosed in this
notice if the aquisitions or disposals are of a kind referred to in section 297(2)(a) of the
Financial Markets Conduct Act 2013; or
(b) in any other case, 5 trading days after the first acquisition or disposal
disclosed in this notice.